Literature DB >> 25556724

A case of metastatic pancreatic adenocarcinoma with prolonged survival after combination of neoadjuvant FOLFIRINOX therapy and synchronous distal pancreatectomy and hepatectomy.

Kyriakos Neofytou1, Alexandros Giakoustidis, Elizabeth C Smyth, David Cunningham, Satvinder Mudan.   

Abstract

In this case report we detail the treatment of a patient with pancreatic ductal adenocarcinoma and a solitary liver metastasis who received nine cycles of FOLFIRINOX therapy with favourable response. The patient subsequently underwent synchronous distal pancreatectomy and hepatectomy with an R0 resection followed by three further cycles of FOLFIRINOX. At the last follow-up, 2 years from operation and 28 months from the diagnosis of metastatic pancreatic adenocarcinoma the patient remains disease free.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  FOLFIRINOX; metastatic pancreatic adenocarcinoma; neoadjuvant; resection; surgery

Mesh:

Substances:

Year:  2014        PMID: 25556724     DOI: 10.1002/jso.23867

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  5 in total

1.  Primary Tumor Resection Following Favorable Response to Systemic Chemotherapy in Stage IV Pancreatic Adenocarcinoma with Synchronous Metastases: a Bi-institutional Analysis.

Authors:  G Paul Wright; Katherine E Poruk; Mazen S Zenati; Jennifer Steve; Nathan Bahary; Melissa E Hogg; Amer H Zuriekat; Christopher L Wolfgang; Herbert J Zeh; Matthew J Weiss
Journal:  J Gastrointest Surg       Date:  2016-09-07       Impact factor: 3.452

2.  Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma with synchronous liver metastasis after treatment with FOLFIRINOX.

Authors:  Kentaro Ozaki; Hiromitsu Hayashi; Yoshiaki Ikuta; Toshiro Masuda; Shinichi Akaboshi; Kenichi Ogata; Katsutaka Matumoto; Katsuhiro Ogawa; Takihiro Kamio; Hideo Baba; Hiroshi Takamori
Journal:  Clin J Gastroenterol       Date:  2019-04-15

3.  Time to think: Selecting patients who may benefit from synchronous resection of primary pancreatic cancer and liver metastases.

Authors:  Si Shi; Xian-Jun Yu
Journal:  World J Gastroenterol       Date:  2018-09-07       Impact factor: 5.742

4.  Simultaneous resection of the primary tumour and liver metastases after conversion chemotherapy versus standard therapy in pancreatic cancer with liver oligometastasis: protocol of a multicentre, prospective, randomised phase III control trial (CSPAC-1).

Authors:  Miaoyan Wei; Si Shi; Jie Hua; Jin Xu; Xianjun Yu
Journal:  BMJ Open       Date:  2019-12-08       Impact factor: 2.692

5.  Individualized Prediction of Survival Benefits of Pancreatectomy Plus Chemotherapy in Patients With Simultaneous Metastatic Pancreatic Cancer.

Authors:  Duorui Nie; Guihua Lai; Guilin An; Zhuojun Wu; Shujun Lei; Jing Li; Jianxiong Cao
Journal:  Front Oncol       Date:  2021-09-16       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.